US20240285622A1 - Pazopanib oral pharmaceutical composition, and preparation method therefor and use thereof - Google Patents

Pazopanib oral pharmaceutical composition, and preparation method therefor and use thereof Download PDF

Info

Publication number
US20240285622A1
US20240285622A1 US18/293,485 US202218293485A US2024285622A1 US 20240285622 A1 US20240285622 A1 US 20240285622A1 US 202218293485 A US202218293485 A US 202218293485A US 2024285622 A1 US2024285622 A1 US 2024285622A1
Authority
US
United States
Prior art keywords
pazopanib
pharmaceutical composition
water
ethanol
glycerol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/293,485
Other languages
English (en)
Inventor
Zhen Guo
Xuan Wang
Pengcheng LU
Jun Fu
Tingting Wang
Shuhuan YING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Aurora Biotechnology Co Ltd
Original Assignee
Shanghai Aurora Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Aurora Biotechnology Co Ltd filed Critical Shanghai Aurora Biotechnology Co Ltd
Assigned to SHANGHAI AURORA BIOTECHNOLOGY CO., LTD. reassignment SHANGHAI AURORA BIOTECHNOLOGY CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WANG, TINGTING, YING, Shuhuan, LU, Pengcheng, WANG, XUAN, FU, JUN, GUO, ZHEN
Publication of US20240285622A1 publication Critical patent/US20240285622A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Definitions

  • the present disclosure relates to a pazopanib oral pharmaceutical composition, a preparation method therefor and use thereof.
  • Renal cell carcinoma renal cancer for short, is one of the most common tumors in the urinary system, with the morbidity accounting for 2% of adult malignant tumors. In China, the morbidity of renal cell carcinoma ranks second among urinary tumors, second only to bladder cancer. With the continuous progress of diagnostic technologies, renal cancer patients have been treated earlier. The overall 5-year survival rate for renal cancer reaches 74%, but the number of advanced metastasis patients is only 12%.
  • VEGF Vascular endothelial growth factor
  • VEGF Vascular endothelial growth factor
  • VEGF receptor tyrosine kinase specifically and highly expressed on the surface of neovascular endothelial cells, activates tyrosine kinase, and thus plays a biological function. Therefore, tumor vascular targeting therapy (which means using VEGF receptor tyrosine kinase inhibitors) targeting VEGF receptor tyrosine kinase has become a new approach for tumor therapy in recent years.
  • Pazopanib (5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide) is a novel oral angiogenesis inhibitor developed by GlaxoSmithKline that can interfere with neovascularization required for the survival and growth of refractory tumors, targets the vascular endothelial growth factor receptors (VEGFRs), and acts by inhibiting neovascularization of the blood supply to tumors. It is a drug that can treat a variety of tumors, and has shown positive results in large-scale clinical trials involving patients with soft tissue sarcoma and renal cell carcinoma.
  • Pazopanib is a BCS II drug, belonging to insoluble hypertonic drugs.
  • the low solubility limits its bioavailability, and in order to enable pazopanib to be quickly dissolved out, improve the bioavailability and reduce side effects, the research on a pharmaceutical composition with immediate-release property has important social and economic values.
  • a pazopanib formulation that has simple preparation process, easy scale-up production, more convenient dosage adjustment and good patient compliance is continuously developed.
  • the present disclosure provides a pazopanib oral pharmaceutical composition, which comprises an active drug, a polymeric carrier, an organic solvent and/or water, wherein the active drug is 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide as represented by formula I or a salt thereof;
  • the pazopanib oral pharmaceutical composition comprises: an active drug, a polymeric carrier, an organic solvent, and water, wherein the active drug is 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide represented by formula I or a salt thereof; the pH value of the pazopanib oral pharmaceutical composition is 3.0-4.5;
  • the polymeric carrier is selected from one or more of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (soluplus), poloxamer, polyethylene glycol vitamin E succinate (TPGS), 15-hydroxystearic acid polyethylene glycol ester, polyoxyethylene 40 hydrogenated castor oil, polyoxyl 35 hydrogenated castor oil, povidone, crospovidone, hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose, polyvinyl alcohol, tween 80, polyvinylpyrrolidone (PVP), and polyethylene glycol; as an example, the polymeric carrier is selected from a combination of soluplus and PVP, a combination of soluplus and TPGS, a combination of TPGS and HPMC, and soluplus.
  • soluplus polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer
  • TPGS polyethylene glycol vitamin E succ
  • the weight ratio of the active drug to the polymeric carrier is 1:10-10:1, e.g., 3:10, 3:8, 3:5, 2:5, 10:1, 2:1, 1:2, 5:16, 1:4, or 1:8.
  • the active drug is preferably 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide hydrochloride (pazopanib hydrochloride).
  • the concentration of the active drug is 5-20 mg/mL, such as, 6-15 mg/mL, as an example, 7 mg/mL, 7.5 mg/mL, 8 mg/mL, 9 mg/mL, 10 mg/mL, 11 mg/mL, 12 mg/mL, 12.5 mg/mL, 13 mg/mL, or 14 mg/mL.
  • the organic solvent is selected from one or more of ethanol, propylene glycol, glycerol, polyethylene glycol-300, polyethylene glycol-400, and polyethylene glycol-600; as an example, the organic solvent is selected from a combination of ethanol and glycerol, and a combination of ethanol, propylene glycol and glycerol.
  • the volume ratio of the organic solvent to the pazopanib pharmaceutical composition is 0.3-0.9, and the volume ratio refers to the ratio of the volume of the organic solvent to the total volume of the pazopanib pharmaceutical composition; as an example, the volume ratio is 0.3, 0.4, 0.5, 0.6, 0.7, 0.75, 0.8, 0.85, or 0.9.
  • the volume ratio of the water to the pazopanib pharmaceutical composition is 0.1-0.7, and the volume ratio refers to the ratio of the volume of the water to the total volume of the pazopanib pharmaceutical composition; as an example, the volume ratio is 0.1, 0.15, 0.2, 0.25, or 0.3.
  • the pazopanib oral pharmaceutical composition may further comprise a sweetener.
  • the sweetener is selected from one or more of aspartame, sucralose, fructose, sucrose, stevioside, glycyrrhizin, essence, spices, saccharin and sodium saccharin.
  • the mass ratio of the sweetener to the active drug is 1:5-5:1, such as 1:3, 1:4, or 2:1.
  • the pazopanib oral pharmaceutical composition may be in any one of the following formulas:
  • the present disclosure further provides a method for preparing the pazopanib pharmaceutical composition, which comprises the following steps:
  • the filtration is filtration through a filter membrane, and the pore size of the filter membrane may be 0.01 ⁇ m to 1.0 ⁇ m, such as 0.45 ⁇ m.
  • the present disclosure further provides use of the pazopanib oral pharmaceutical composition for the manufacture of a medicament for treating and/or preventing a tumor.
  • the tumor may be renal cancer or soft tissue sarcoma.
  • the present disclosure further provides use of the pazopanib oral pharmaceutical composition for manufacturing of a pharmaceutical formulation.
  • the present disclosure further provides a pharmaceutical formulation comprising the pazopanib oral pharmaceutical composition.
  • the pharmaceutical formulation may be an oral liquid.
  • the present disclosure further provides a method for treating and/or preventing a tumor, which comprises administering to populations in need thereof a therapeutically effective amount of the pazopanib oral pharmaceutical composition or the pharmaceutical formulation.
  • the present disclosure provides a pazopanib oral pharmaceutical composition, a preparation method therefor and use thereof, aiming at overcoming the defects of low solubility, low bioavailability, large side effect, poor patient compliance and the like of pazopanib in the prior art.
  • Pazopanib in the composition or the formulation of the present disclosure is dispersed in a solution form, so the solubility and the dissolution speed of pazopanib can be significantly improved, the bioavailability of the drug is significantly improved, and pazopanib has the advantages of high solubility, high dissolution speed and high bioavailability, and can both improve patient compliance and solve the problems of dysphagia in elderly patients and the like.
  • Example 10 Pazopanib Active 200 mg 200 mg 250 mg 250 mg 250 mg 250 mg hydrochloride ingredient (10 mg/ml) (10 mg/ml) (12.5 mg/ml) (12.5 mg/ml) (12.5 mg/ml) Soluplus Carrier 100 mg 400 mg 800 mg 1000 mg 2000 mg material (5 mg/ml) (20 mg/ml) (40 mg/ml) (50 mg/ml) (100 mg/ml) TPGS Carrier / / / / / material PVP Carrier / / / / / material HPMC Carrier / / / / / material Ethanol Solvent 5 ml 4 ml 5 ml 6 ml 5 ml (25% v/v) (20% v/v) (25% v/v) (30% v/v) (25% v/v) Propylene glycol Solvent / 3 ml / 2 ml 3 ml (15%
  • the preparation process comprises the following steps: according to the formulas described above,
  • the pazopanib oral solution was prepared according to the pharmaceutical formulation formulas listed in the ten examples described above, the pH value of the solution was adjusted to be 3.0-4.5, and the solution was packaged by adopting a brown bottle.
  • the present disclosure prepared the pazopanib oral solution as in Example 7, and carried out influencing factor testing including high-temperature (60° C.) testing, high-humidity (90% RH ⁇ 5% RH) testing, illumination (total illumination: 1.2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 Lux hr, total ultraviolet irradiance 200 W ⁇ hr/m 2 ) testing and accelerated testing (40° C./75% RH), and the results are shown in Table 3 below.
  • the pazopanib oral solution was prepared as in Example 7, with a commercially available pazopanib tablet (VOTRIENT, 200 mg/tablet) as a control formulation.
  • Beagle dogs were orally administered with the pazopanib oral solution at a dose of 50 mg/dog/day and 100 mg/dog/day, respectively, beagle dogs were orally administered with VOTRIENT at a dose of 200 mg/dog/day, and pharmacokinetic properties of the control formulation and the test formulation at different doses in beagle dogs were examined.
  • the pharmacokinetic results are shown in Table 4, and PK curves are shown in FIG. 1 .
  • Test results show that the exposure amount of the API could be still significantly improved on the premise that the dosage of the API was 2 times and 4 times lower than that of a control dose in Example 7, and the oral bioavailability was significantly improved.
  • the pazopanib oral solution of the present disclosure has good stability, can improve the mouthfeel of the formulation, and has remarkably improved bioavailability compared with the control formulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
US18/293,485 2021-07-30 2022-07-28 Pazopanib oral pharmaceutical composition, and preparation method therefor and use thereof Pending US20240285622A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110871277 2021-07-30
CN202110871277.1 2021-07-30
PCT/CN2022/108602 WO2023006029A1 (zh) 2021-07-30 2022-07-28 帕唑帕尼口服药物组合物、其制备方法及应用

Publications (1)

Publication Number Publication Date
US20240285622A1 true US20240285622A1 (en) 2024-08-29

Family

ID=85061091

Family Applications (1)

Application Number Title Priority Date Filing Date
US18/293,485 Pending US20240285622A1 (en) 2021-07-30 2022-07-28 Pazopanib oral pharmaceutical composition, and preparation method therefor and use thereof

Country Status (6)

Country Link
US (1) US20240285622A1 (zh)
EP (1) EP4378451A1 (zh)
JP (1) JP2024528736A (zh)
CN (1) CN115671110B (zh)
TW (1) TW202313043A (zh)
WO (1) WO2023006029A1 (zh)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
CN1303994C (zh) * 2003-03-03 2007-03-14 浙江海正药业股份有限公司 紫杉醇囊泡注射剂及其制备方法
EP2140861A1 (en) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
EP4218740A1 (en) * 2012-01-13 2023-08-02 XSpray Pharma AB (publ) Novel compositions
CN104586770A (zh) * 2014-12-30 2015-05-06 山东博迈康药物研究有限公司 一种盐酸帕唑帕尼的热熔挤出制剂及其制备方法
CN105983098B (zh) * 2015-01-30 2020-02-21 湖北生物医药产业技术研究院有限公司 用于提高难溶性的抗肿瘤药物生物利用度的固体组合物及其制备方法
JP6878417B2 (ja) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド 剤形およびそれらの使用
TWI770624B (zh) * 2018-06-15 2022-07-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途

Also Published As

Publication number Publication date
CN115671110A (zh) 2023-02-03
JP2024528736A (ja) 2024-07-30
EP4378451A1 (en) 2024-06-05
WO2023006029A1 (zh) 2023-02-02
TW202313043A (zh) 2023-04-01
CN115671110B (zh) 2024-05-10

Similar Documents

Publication Publication Date Title
ES2731601T3 (es) Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo
ES2258566T3 (es) Combinaciones de farmacos (por ejemplo, clorpromacina y pentamidina) para el tratamiento de trastornos neoplasicos.
US8791150B2 (en) Pharmaceutical composition for peroral administration of diindolylmethane
JP2021503494A (ja) ペメトレキセドを含む経口用医薬組成物及びその製造方法
JP2022514569A (ja) 非晶質スパルセンタン組成物
KR102573278B1 (ko) 약학적 조성물 및 이의 용도
US20240285622A1 (en) Pazopanib oral pharmaceutical composition, and preparation method therefor and use thereof
US20230310393A1 (en) Sorafenib pharmaceutical composition with high bioavailability and use thereof
US12090153B2 (en) Combination therapy for the treatment of uveal melanoma
AU2006257428B2 (en) Oral solid pharmaceutical formulation of the tubulin inhibitor indibulin
US10966964B2 (en) Method for preparing pharmaceutical composition comprising pyrrolo-fused six-membered heterocyclic compound
WO2023093640A1 (zh) 一种达罗他胺药物组合物及其制备方法和用途
EP3811948B1 (en) Glycosides for use in preventing and treating diabetic complications
CN112292117A (zh) 包含依鲁替尼的配制品/组合物
US20190054073A1 (en) Pharmaceutical composition comprising pyrrolo-fused six-membered heterocyclic compound
WO2023035200A1 (zh) 五氟利多在制备治疗子宫内膜癌的药物中的应用
Gupta et al. Preformulation studies of diltiazem hydrochloride from tableted microspheres
US20230105701A1 (en) Dissolution-enhanced olaparib composition
US20120289553A1 (en) Oral liquid pharmaceutical composition of nifedipine
CN117693333A (zh) 一种低服用剂量高药物暴露量的索拉非尼或多纳非尼口服制剂及其应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHANGHAI AURORA BIOTECHNOLOGY CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GUO, ZHEN;WANG, XUAN;LU, PENGCHENG;AND OTHERS;SIGNING DATES FROM 20231219 TO 20231221;REEL/FRAME:066294/0051

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION